Want to see OMER full AI Analyst Report?
OMER Stock Chart & Stats
$18.22
$1.72(17.57%)
At close: 4:00 PM EDT
$18.22
$1.72(17.57%)
Day’s Range― - ―
52-Week Range$6.24 - $21.24
Previous CloseN/A
Volume2.32M
Average Volume (3M)1.41M
Market Cap
$1.18B
Enterprise Value$1.02B
Total Cash (Recent Filing)$131.95M
Total Debt (Recent Filing)$83.77M
Price to Earnings (P/E)8.7
Beta1.41
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.91
Shares Outstanding72,388,310
10 Day Avg. Volume1,259,294
30 Day Avg. Volume1,406,679
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue26.48
Enterprise Value/Gross Profit27.64
Enterprise Value/Ebitda7.65
Forecast
1Y Price Target
$27.50Price Target Upside50.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.8
Revenue Forecast (FY)$127.50M
Bulls Say, Bears Say
Bulls Say
Yartemlia Launch TractionRapid growth in Yartemlia sales during its first full quarter demonstrates meaningful commercial adoption and expanding market reach. If prescribing and account growth continue, the product can become a more durable source of operating revenue and help support investment in Omeros’s broader pipeline.
U.S. Reimbursement SupportA permanent product-specific J-code and substantial NTAP reimbursement improve the reimbursement infrastructure supporting Yartemlia in the U.S. These measures can reduce administrative friction for hospitals, strengthen payer economics, and support broader adoption across transplant centers over the next several quarters.
Pipeline And Partnership DepthProgress across MASP-2, PDE7, and oncology programs gives Omeros multiple opportunities beyond its current commercial launch. The Novo Nordisk relationship also provides strategic validation and potential non-dilutive funding, increasing the company’s ability to develop additional assets over time.
Bears Say
European Regulatory SetbackThe repeated negative European opinion removes a near-term regional approval opportunity for narsoplimab and limits geographic expansion of the product. Although Omeros is pursuing additional indications, the setback raises regulatory execution risk and may concentrate commercial dependence on the U.S. market.
Negative Shareholder EquityNegative equity indicates that liabilities exceed the recorded asset base and reduces financial flexibility even after substantial debt reduction. This capital structure can constrain future financing choices, increase refinancing sensitivity, and make it harder to absorb setbacks while funding commercial and pipeline investment.
Cash-flow DurabilityThe return to sizable operating cash burn shows that reported earnings have not yet translated into consistent internal funding. Continued outflows could require additional financing or tighter spending, while rising launch and R&D expenses may delay management’s target of company-wide positive cash flow by mid-2027.
Omeros News
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $6.24 and its highest was $21.24 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $1.18B.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Aug 12, 2026. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.418.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is 0.02.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 72,388,310 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of $0.15 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went up 26.55%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (50.93% Upside)
$27.50 (50.93% Upside)
Blogger Sentiment
Bullish
OMER Sentiment 94%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 23.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.60%
12-Months-Change
Fundamentals
Return on Equity
-109.40%
Trailing 12-Months
Asset Growth
43.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Omeros Corp
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
OMER Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a successful commercial launch for Yartemlia with very strong quarter-over-quarter sales growth (190% gross, 188% net), positive operating cash flow, meaningful balance sheet improvements via share and note repurchases, reimbursement wins (J-code and NTAP), and progress across a diversified pipeline and strategic partnership with Novo Nordisk. Offsetting items include a negative CHMP opinion in Europe, accounting volatility from derivative mark-to-market adjustments and repurchase-related losses, expected near-term increases in operating expenses, limited patient-level visibility, and one-time reimbursement items that temper recurring income visibility. On balance, the operational and commercial positives—especially the rapid U.S. uptake, cash generation, and reduced leverage/dilution—outweigh the challenges, which are largely manageable or noncash/one-time in nature.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$27.50
▲(50.93% Upside)
Technical Analysis
Ownership Overview
3.73% Insiders
7.87% Mutual Funds
0.16% Other Institutional Investors
75.19% Public Companies and
Individual Investors